62nd ASH Annual Meeting

The 62nd ASH Annual Meeting will be held from December 2-11, 2020, virtually.

There will be one oral presentation of initial data for Cellectis-sponsored BALLI-01 clinical trial evaluating UCART22 product candidate, and one Trials in Progress poster presentation of Cellectis-sponsored AMELI-01 clinical trial evaluating UCART123 product candidate.

Oral Abstract Session:

Abstract: #163

Title: Preliminary results of BALLI-01: A Phase I study of UCART22 (allogeneic engineered T-cells expressing anti-CD22 Chimeric Antigen Receptor) in adult patients with relapsed or refractory (R/R) CD22+ B-cell Acute Lymphoblastic Leukemia (B-ALL).
Presenter: Jain Nitin, MD, The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX

Session Name: 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Chimeric Antigen Receptor T Cell Therapy

Session Release Date & Time: Saturday, December 5, 2020 at 1:00 PM Pacific Time

Poster Abstract Session:

Abstract: #1039

Title: AMELI-01: Phase I, open label dose-escalation and dose-expansion study to evaluate the safety, expansion, persistence and clinical activity of UCART123 (allogeneic engineered T-cells expressing anti-CD123 chimeric antigen receptor), administered in patients with Relapsed/Refractory Acute Myeloid Leukemia

Presenter: Gail J. Roboz, MD, Professor of Medicine at Weill Cornell Medicine and New York-Presbyterian, New York, NY

Session Name: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster I

Session Release Date & Time: Date: Saturday, December 5, 2020

The Virtual Poster Hall will be open for attendees to browse a different set of posters each day. The Poster Hall hours are as follows:

Saturday, December 5: 7:00 AM - 3:30 PM Pacific Time
Sunday, December 6: 7:00 AM - 3:30 PM Pacific Time
Monday, December 7: 7:00 AM - 3:00 PM Pacific Time